122 related articles for article (PubMed ID: 36815548)
1. Trends in risk factor control and treatment among patients with non-alcoholic fatty liver disease and type 2 diabetes between 2000 and 2020: A territory-wide study.
Zhang X; Yip TC; Tse YK; Hui VW; Li G; Lin H; Liang LY; Lai JC; Lai MS; Cheung JTK; Chan HL; Chan SL; Kong AP; Wong GL; Wong VW
Aliment Pharmacol Ther; 2023 May; 57(10):1103-1116. PubMed ID: 36815548
[TBL] [Abstract][Full Text] [Related]
2. Risk of liver-related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease.
Zhang X; Wong GL; Yip TC; Cheung JTK; Tse YK; Hui VW; Lin H; Lai JC; Chan HL; Kong AP; Wong VW
Hepatology; 2022 Nov; 76(5):1409-1422. PubMed ID: 35334125
[TBL] [Abstract][Full Text] [Related]
3. The Relationship Between Glycaemic Control and Non-Alcoholic Fatty Liver Disease in Nigerian Type 2 Diabetic Patients.
Afolabi BI; Ibitoye BO; Ikem RT; Omisore AD; Idowu BM; Soyoye DO
J Natl Med Assoc; 2018 Jun; 110(3):256-264. PubMed ID: 29778128
[TBL] [Abstract][Full Text] [Related]
4. Duration of type 2 diabetes and liver-related events in nonalcoholic fatty liver disease: A landmark analysis.
Zhang X; Yip TC; Tse YK; Hui VW; Li G; Lin H; Liang LY; Lai JC; Chan HL; Chan SL; Kong AP; Wong GL; Wong VW
Hepatology; 2023 Dec; 78(6):1816-1827. PubMed ID: 37119179
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of high sensitivity C-reaction protein in non-insulin dependent diabetes mellitus patients with non-alcoholic fatty liver disease.
Bi Y; Min M; Shen W; Deng P; Du Q; Dong M; Liu Y
Int J Clin Exp Pathol; 2015; 8(7):8494-9. PubMed ID: 26339423
[TBL] [Abstract][Full Text] [Related]
6. Associations of lipid parameters with non-alcoholic fatty liver disease in type 2 diabetic patients according to obesity status and metabolic goal achievement.
Zhu Z; Yang N; Fu H; Yuan G; Chen Y; Du T; Zhou X
Front Endocrinol (Lausanne); 2022; 13():1002099. PubMed ID: 36187115
[TBL] [Abstract][Full Text] [Related]
7. Glycemic Measures and Development and Resolution of Nonalcoholic Fatty Liver Disease in Nondiabetic Individuals.
Wang B; Li M; Zhao Z; Wang S; Lu J; Chen Y; Xu M; Wang W; Ning G; Bi Y; Wang T; Xu Y
J Clin Endocrinol Metab; 2020 May; 105(5):. PubMed ID: 32144419
[TBL] [Abstract][Full Text] [Related]
8. Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany.
Labenz C; Huber Y; Kalliga E; Nagel M; Ruckes C; Straub BK; Galle PR; Wörns MA; Anstee QM; Schuppan D; Schattenberg JM
Aliment Pharmacol Ther; 2018 Nov; 48(10):1109-1116. PubMed ID: 30288767
[TBL] [Abstract][Full Text] [Related]
9. Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes.
Cusi K; Sanyal AJ; Zhang S; Hartman ML; Bue-Valleskey JM; Hoogwerf BJ; Haupt A
Diabetes Obes Metab; 2017 Nov; 19(11):1630-1634. PubMed ID: 28417532
[TBL] [Abstract][Full Text] [Related]
10. Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus.
Fischer LT; Hochfellner DA; Knoll L; Pöttler T; Mader JK; Aberer F
Cardiovasc Diabetol; 2021 Apr; 20(1):89. PubMed ID: 33894772
[TBL] [Abstract][Full Text] [Related]
11. Serum Ferritin level, microalbuminuria and non-alcoholic fatty liver disease in type 2 diabetic patients.
Amin RF; El Bendary AS; Ezzat SE; Mohamed WS
Diabetes Metab Syndr; 2019; 13(3):2226-2229. PubMed ID: 31235161
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and clinical characteristics of non-alcoholic fatty liver disease in newly diagnosed patients with ketosis-onset diabetes.
Li TT; Wang AP; Lu JX; Chen MY; Zhao CC; Tang ZH; Li LX; Jia WP
Diabetes Metab; 2018 Nov; 44(5):437-443. PubMed ID: 29631765
[TBL] [Abstract][Full Text] [Related]
13. [The relationship between non-alcoholic fatty liver disease and metabolic syndrome in patients with latent autoimmune diabetes in adults].
Yu TP; Zhao CC; Chen MY; Lu JX; Li LX; Jia WP
Zhonghua Yi Xue Za Zhi; 2018 Aug; 98(30):2398-2402. PubMed ID: 30138983
[No Abstract] [Full Text] [Related]
14. Post hoc analyses of surrogate markers of non-alcoholic fatty liver disease (NAFLD) and liver fibrosis in patients with type 2 diabetes in a digitally supported continuous care intervention: an open-label, non-randomised controlled study.
Vilar-Gomez E; Athinarayanan SJ; Adams RN; Hallberg SJ; Bhanpuri NH; McKenzie AL; Campbell WW; McCarter JP; Phinney SD; Volek JS; Chalasani N
BMJ Open; 2019 Feb; 9(2):e023597. PubMed ID: 30803948
[TBL] [Abstract][Full Text] [Related]
15. Impact of Non-Alcoholic Fatty Liver Disease on Metabolic Comorbidities in Type 2 Diabetes Mellitus.
Labenz C; Kostev K; Alqahtani SA; Galle PR; Schattenberg JM
Exp Clin Endocrinol Diabetes; 2022 Mar; 130(3):172-177. PubMed ID: 33601426
[TBL] [Abstract][Full Text] [Related]
16. Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study.
Strain WD; Lukashevich V; Kothny W; Hoellinger MJ; Paldánius PM
Lancet; 2013 Aug; 382(9890):409-416. PubMed ID: 23706759
[TBL] [Abstract][Full Text] [Related]
17. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population.
Feng RN; Du SS; Wang C; Li YC; Liu LY; Guo FC; Sun CH
World J Gastroenterol; 2014 Dec; 20(47):17932-40. PubMed ID: 25548491
[TBL] [Abstract][Full Text] [Related]
18. Trends in drug prescriptions for type 2 diabetes, hypertension, and dyslipidemia among adults with non-alcoholic fatty liver disease.
Machida T; Obara T; Miyazaki M; Inoue J; Mano N
Ann Hepatol; 2022; 27(4):100699. PubMed ID: 35278680
[TBL] [Abstract][Full Text] [Related]
19. A Prediction Model Based on Noninvasive Indicators to Predict the 8-Year Incidence of Type 2 Diabetes in Patients with Nonalcoholic Fatty Liver Disease: A Population-Based Retrospective Cohort Study.
Cai X; Zhu Q; Cao Y; Liu S; Wang M; Wu T; Hong J; Ahmat A; Aierken X; Li N
Biomed Res Int; 2021; 2021():5527460. PubMed ID: 34095297
[TBL] [Abstract][Full Text] [Related]
20. Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound.
Petrović G; Bjelaković G; Benedeto-Stojanov D; Nagorni A; Brzački V; Marković-Živković B
Vojnosanit Pregl; 2016 Oct; 73(10):910-20. PubMed ID: 29327896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
